LEADER 03404nam 22007454a 450 001 9910144409203321 005 20200520144314.0 010 $a9786612002069 010 $a9781282002067 010 $a1282002066 010 $a9780470411292 010 $a0470411295 010 $a9780470411285 010 $a0470411287 035 $a(CKB)1000000000577902 035 $a(EBL)406462 035 $a(OCoLC)476225648 035 $a(SSID)ssj0000180255 035 $a(PQKBManifestationID)11183633 035 $a(PQKBTitleCode)TC0000180255 035 $a(PQKBWorkID)10148673 035 $a(PQKB)11311742 035 $a(MiAaPQ)EBC406462 035 $a(Au-PeEL)EBL406462 035 $a(CaPaEBR)ebr10275622 035 $a(CaONFJC)MIL200206 035 $a(PPN)243323271 035 $a(OCoLC)229430563 035 $a(FINmELB)ELB178306 035 $a(Perlego)2769727 035 $a(EXLCZ)991000000000577902 100 $a20080527d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aIntegrated cardiac safety $eassessment methodologies for noncardiac drugs in discovery, development, and postmarketing surveillance /$fJ. Rick Turner, Todd A. Durham 205 $a1st ed. 210 $aHoboken, N.J. $cJohn Wiley & Sons$dc2009 215 $a1 online resource (500 p.) 300 $aDescription based upon print version of record. 311 08$a9780470229644 311 08$a0470229640 320 $aIncludes bibliographical references (p. 397-455) and index. 327 $aThe importance of cardiac safety assessments -- The biological basis of adverse drug reactions -- Cardiac structure and function -- Cardiac pathophysiology and disease -- Drug discovery and drug design -- Nonclinical development -- The thorough QT/QTc trial -- General safety assessments -- Therapeutic use trials and meta-analyses -- Assessment methodologies in nonexperimental postmarketing surveillance -- Postmarketing proarrhythmic cardiac safety assessments -- Generalized cardiac safety -- Medication errors, adherence, and concordance -- Future directions in drug safety. 330 $aThe serious nature of cardiovascular adverse drug reactions occurring in patients makes assessment of a drug's cardiac safety profile a high priority during both development and post-approval monitoring. Integrated Cardiac Safety provides necessary guidance and methodology for professionals assessing cardiac safety of drugs throughout all stages of the drug's life, from discovery and development through postmarketing research. This self-contained, reader-friendly text is valuable to professionals in the pharmaceutical, biotechnology, and CRO industries, pharmacologists, toxicologists, g 606 $aCardiovascular toxicology 606 $aHeart$xEffect of drugs on 606 $aDrugs$xSide effects$xTesting 606 $aDrugs$xSafety measures 615 0$aCardiovascular toxicology. 615 0$aHeart$xEffect of drugs on. 615 0$aDrugs$xSide effects$xTesting. 615 0$aDrugs$xSafety measures. 676 $a616.1/23061 700 $aTurner$b J. Rick$0281064 701 $aDurham$b Todd A$0970651 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910144409203321 996 $aIntegrated cardiac safety$92206214 997 $aUNINA